Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nuwellis (NUWE)
NASDAQ:NUWE
Holding NUWE?
Track your performance easily
NUWE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.00 - $31.15
Previous Close$1.24
Volume243.89K
Average Volume (3M)2.78M
Market Cap
$5.42M
Enterprise Value$4.12M
Total Cash (Recent Filing)$1.91M
Total Debt (Recent Filing)$600.00K
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Mar 04, 2025EPS Estimate
-$0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-116.60
Shares Outstanding4,373,968
10 Day Avg. Volume3,043,556
30 Day Avg. Volume2,775,213
Standard Deviation0.36
R-Squared0.00273
Alpha-0.12
Financial Highlights & Ratios
Price to Book (P/B)1.78
Price to Sales (P/S)0.65
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.46
Enterprise Value/Gross Profit0.83
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$16.00Price Target Upside1222.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Nuwellis News
PremiumCompany Announcements
Nuwellis, Inc. Reports Strong Q3 Financial PerformanceBulls Say, Bears Say
Bulls Say
Reimbursement And Patient AccessThe CMS will reassign the Aquadex ultrafiltration code to increase reimbursement rates, which should provide a profitable reimbursement pathway and expand the number of patients who can receive the therapy.
Revenue GrowthStrong growth in Pediatric revenue, up 28% year-over-year, following the addition of three new accounts during the quarter.
Strategic Focus And ExpansionThe termination of the distribution agreement with SeaStar allows Nuwellis to focus exclusively on its Aquadex therapy and build on momentum in adding new accounts.
Bears Say
Cash FlowEven with the higher reimbursement rates, the company is not expected to operate on a positive cash flow basis through at least 2026.
ProfitabilityThe timeline towards profitability remains unclear, likely requiring additional dilutive capital raises, which dampens the investment outlook.
UtilizationThe y/y decline in the quarter in pediatric utilization gives some concern.
---
Ownership Overview
―
Insiders
0.10% Mutual Funds
― Other Institutional Investors
99.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NUWE FAQ
What was Nuwellis’s price range in the past 12 months?
Nuwellis lowest stock price was $1.00 and its highest was $31.15 in the past 12 months.
What is Nuwellis’s market cap?
Currently, no data Available
When is Nuwellis’s upcoming earnings report date?
Nuwellis’s upcoming earnings report date is Mar 04, 2025 which is in 101 days.
How were Nuwellis’s earnings last quarter?
Nuwellis released its earnings results on Nov 11, 2024. The company reported $1.74 earnings per share for the quarter, beating the consensus estimate of -$1.28 by $3.02.
Is Nuwellis overvalued?
According to Wall Street analysts Nuwellis’s price is currently Undervalued.
Does Nuwellis pay dividends?
Nuwellis does not currently pay dividends.
What is Nuwellis’s EPS estimate?
Nuwellis’s EPS estimate is -$0.43.
How many shares outstanding does Nuwellis have?
Nuwellis has 4,373,968 shares outstanding.
What happened to Nuwellis’s price movement after its last earnings report?
Nuwellis reported an EPS of $1.74 in its last earnings report, beating expectations of -$1.28. Following the earnings report the stock price went up 13.26%.
Which hedge fund is a major shareholder of Nuwellis?
Currently, no hedge funds are holding shares in NUWE
---
Nuwellis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (1222.31% Upside)
$16.00 (1222.31% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 15.5%
Last 30 Days ▲ 15.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.17%
12-Months-Change
Fundamentals
Return on Equity
-276.02%
Trailing 12-Months
Asset Growth
-41.15%
Trailing 12-Months
Company Description
Nuwellis
CHF Solutions, Inc. is a medical device company, which engages in the provision of products for the treatment of fluid overload. Its product include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
---
NUWE Earnings Call
Q3 2024
0:00 / 0:00
---
NUWE Stock 12 Month Forecast
Average Price Target
$16.00
▲(1222.31% Upside)
Technical Analysis
Best Analysts Covering NUWE
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-46.70%
reiterated a buy rating 3 months ago
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -46.70% per trade.
---